Limits...
The Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 Status.

Kruschewski M, Mueller K, Lipka S, Budczies J, Noske A, Buhr HJ, Elezkurtaj S - Cancers (Basel) (2011)

Bottom Line: Overall survival was significantly better in patients with p53-positive carcinomas than in those without p53 expression (p = 0.048).No differences were found in recurrence-free survival (p = 0.161).Patients with p53+/p21- carcinomas had significantly better overall and recurrence-free survival than those with p53+/p21+ (p < 0.0001 resp. p = 0.003).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Campus Benjamin Franklin, Charité-University Medicine Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. martin.kruschewski@charite.de.

ABSTRACT
The prognostic value of p53 and p21 expression in colorectal cancer is still under debate. We hypothesize that the prognostic impact of p53 expression is dependent on p21 status. The expression of p53 and p21 was immunohistochemically investigated in a prospective cohort of 116 patients with UICC stage II and III sporadic colorectal cancer. The results were correlated with overall and recurrence-free survival. The mean observation period was 51.8 ± 2.5 months. Expression of p53 was observed in 72 tumors (63%). Overall survival was significantly better in patients with p53-positive carcinomas than in those without p53 expression (p = 0.048). No differences were found in recurrence-free survival (p = 0.161). The p53+/p21- combination was seen in 68% (n = 49), the p53+/p21+ combination in 32% (n = 23). Patients with p53+/p21- carcinomas had significantly better overall and recurrence-free survival than those with p53+/p21+ (p < 0.0001 resp. p = 0.003). Our data suggest that the prognostic impact of p53 expression on sporadic colorectal cancer is dependent on p21 status.

No MeSH data available.


Related in: MedlinePlus

Overall survival (A) and recurrence-free survival (B) in relation to p53 expression (n = 114).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3756413&req=5

f1-cancers-03-01274: Overall survival (A) and recurrence-free survival (B) in relation to p53 expression (n = 114).

Mentions: Univariate Kaplan-Meier analysis showed that overall survival was significantly better in patients with p53-positive carcinomas than in those without p53 expression (mean value 83.4 ± 4.9 vs. 60.00 ± 5.1 months) (p = 0.048). Recurrence-free survival did not differ between the two groups (mean value 80.9 ± 5.4 vs. 59.0 ± 5.5 months) (p = 0.161) (Figure 1A, 1B).


The Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 Status.

Kruschewski M, Mueller K, Lipka S, Budczies J, Noske A, Buhr HJ, Elezkurtaj S - Cancers (Basel) (2011)

Overall survival (A) and recurrence-free survival (B) in relation to p53 expression (n = 114).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3756413&req=5

f1-cancers-03-01274: Overall survival (A) and recurrence-free survival (B) in relation to p53 expression (n = 114).
Mentions: Univariate Kaplan-Meier analysis showed that overall survival was significantly better in patients with p53-positive carcinomas than in those without p53 expression (mean value 83.4 ± 4.9 vs. 60.00 ± 5.1 months) (p = 0.048). Recurrence-free survival did not differ between the two groups (mean value 80.9 ± 5.4 vs. 59.0 ± 5.5 months) (p = 0.161) (Figure 1A, 1B).

Bottom Line: Overall survival was significantly better in patients with p53-positive carcinomas than in those without p53 expression (p = 0.048).No differences were found in recurrence-free survival (p = 0.161).Patients with p53+/p21- carcinomas had significantly better overall and recurrence-free survival than those with p53+/p21+ (p < 0.0001 resp. p = 0.003).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Campus Benjamin Franklin, Charité-University Medicine Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. martin.kruschewski@charite.de.

ABSTRACT
The prognostic value of p53 and p21 expression in colorectal cancer is still under debate. We hypothesize that the prognostic impact of p53 expression is dependent on p21 status. The expression of p53 and p21 was immunohistochemically investigated in a prospective cohort of 116 patients with UICC stage II and III sporadic colorectal cancer. The results were correlated with overall and recurrence-free survival. The mean observation period was 51.8 ± 2.5 months. Expression of p53 was observed in 72 tumors (63%). Overall survival was significantly better in patients with p53-positive carcinomas than in those without p53 expression (p = 0.048). No differences were found in recurrence-free survival (p = 0.161). The p53+/p21- combination was seen in 68% (n = 49), the p53+/p21+ combination in 32% (n = 23). Patients with p53+/p21- carcinomas had significantly better overall and recurrence-free survival than those with p53+/p21+ (p < 0.0001 resp. p = 0.003). Our data suggest that the prognostic impact of p53 expression on sporadic colorectal cancer is dependent on p21 status.

No MeSH data available.


Related in: MedlinePlus